{
    "organizations": [],
    "uuid": "d458bf769c059169e685fcf139735cd560330a4a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-recro-pharma-inc-reports-year-end/brief-recro-pharma-inc-reports-year-end-2017-financial-results-idUSASB0C7NQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Recro Pharma Inc Reports Year End 2017 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Recro Pharma Inc:\n* RECRO PHARMA REPORTS YEAR END 2017 FINANCIAL RESULTS * RECRO PHARMA INC - FOR 2018, COMPANY EXPECTS REVENUE GENERATED FROM ITS CDMO DIVISION TO BE APPROXIMATELY $70 MILLION\n* RECRO PHARMA INC - IV MELOXICAM NDA SUBMITTED AND PDUFA ACTION DATE SET FOR MAY 26, 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T20:09:00.000+02:00",
    "crawled": "2018-02-27T14:11:59.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "recro",
        "pharma",
        "inc",
        "recro",
        "pharma",
        "report",
        "year",
        "end",
        "financial",
        "result",
        "recro",
        "pharma",
        "inc",
        "company",
        "expects",
        "revenue",
        "generated",
        "cdmo",
        "division",
        "approximately",
        "million",
        "recro",
        "pharma",
        "inc",
        "iv",
        "meloxicam",
        "nda",
        "submitted",
        "pdufa",
        "action",
        "date",
        "set",
        "may",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}